- Home >
- Clinicals Trials >
- CLEVER-PEPTIDE (IC 2018-06)
Retour à la liste des essais cliniques
CLEVER-PEPTIDE (IC 2018-06)
Open-label, non-controlled, multicenter, dose escalation, first-in-human phase I clinical trial to evaluate the safety, pharmacokinetics and preliminary antitumor activity of intravenous PEP-010, administered as single agent and in combination with paclitaxel in patients with recurrent and/or metastatic solid cancer.
- Ouvert à Paris depuis le : 02/04/2021
- Public cible : Adult
- Phase : Phase I
Description de l'essai
The aim of this study is to determine the maximum tolerated dose and the recommended dose to be used in phase 2 of PEP-010 when administered as single agent, and in combination with paclitaxel by recording the dose-limiting toxicities.
Investigateur principal
